Medical Device Patch Management

Medical device patch management requires specialized procedures that coordinate with device manufacturers and your clinical engineering/biomed teams, so patches are validated and deployed safely in clinical environments. You operationalize this by maintaining an accurate device inventory, establishing a manufacturer-coordinated patch workflow, documenting risk-based decisions (including compensating controls), and retaining evidence that patches were tested, approved, and deployed (or deferred) under defined governance. ¹

Key takeaways:

• Specialized patching for medical devices is a governed workflow, not a routine IT “Patch Tuesday” activity. ¹
• Coordination with manufacturers and clinical engineering is a requirement; document the coordination and outcomes. ¹
• Auditors will look for inventory, decision records, validation/testing evidence, and deployment/deferral tracking tied to patient safety and clinical uptime.

Medical devices sit at the intersection of cybersecurity, patient safety, and clinical operations. That intersection is why generic endpoint patch management programs often fail audits when applied to medical devices without modification. HICP Practice 9.6 calls for specialized patch management procedures that explicitly coordinate with device manufacturers and clinical engineering/biomedical teams, and that validate patches before deployment into clinical environments. ¹

For a Compliance Officer, CCO, or GRC lead, the practical goal is simple: you need a repeatable, documented workflow that shows (1) you know what devices you have, (2) you can obtain patch guidance from the manufacturer/third parties supporting the device, (3) you assess and validate patches in a way that accounts for clinical constraints, and (4) you deploy, track, and verify outcomes or formally approve deferrals with compensating controls. The “specialized” part is not extra paperwork; it’s the governance and clinical validation steps that prevent well-intentioned patching from breaking regulated clinical functions or interrupting patient care.

This page gives you requirement-level implementation guidance you can hand to IT security, clinical engineering, and operations and then audit internally for evidence quality.

Regulatory text

Requirement (HICP Practice 9.6): “Establish specialized patch management procedures for medical devices coordinating with manufacturers and clinical engineering teams.” ¹

Operator interpretation (what you must do):

• Specialized procedures: Your medical device patch process must be distinct from standard IT patching where needed (for example: extra validation steps, clinical maintenance windows, safety checks, and manufacturer constraints). ¹
• Coordinate with manufacturers: You need a defined method to obtain patch guidance, approve patch applicability, and confirm supportability from the manufacturer or other third parties that service the device. ¹
• Coordinate with clinical engineering/biomed: Clinical engineering is a control owner, not a bystander. They must participate in triage, validation, scheduling, deployment, and acceptance back into clinical use. ¹
• Validate before deployment to clinical environments: Maintain evidence that patches were assessed and validated in a way appropriate to the clinical setting prior to broad deployment. ¹

Plain-English requirement (what “good” looks like)

You can explain, device-by-device, how a patch goes from “available” to “safe to deploy” to “deployed and verified,” with documented manufacturer input and clinical engineering sign-off. When you can’t patch quickly, you have a documented risk decision and compensating controls that reduce exposure until patching is feasible. ¹

Who it applies to

Entities

• Healthcare organizations operating clinical environments with connected medical devices. ¹
• Health IT vendors that manage, host, service, or otherwise support medical devices or the systems they depend on (including third parties involved in device maintenance). ¹

Operational context (where this shows up)

• Network-connected or software-driven medical devices in patient care areas.
• Devices supported by manufacturer service agreements, managed service providers, or on-site biomed.
• Environments where downtime, clinical workflow, and patient safety constrain patch timing and methods.

What you actually need to do (step-by-step)

1) Define scope and ownership

1. Declare what counts as a “medical device” in your patch program (include connected devices, device-adjacent systems that are part of the clinical function, and manufacturer-managed components).
2. Assign clear RACI across Information Security, IT Operations, Clinical Engineering/Biomed, and Procurement/Vendor Management.
3. Establish a single intake channel for manufacturer advisories and patch notices (email alias, portal queue, ticket category).

Deliverable: Medical Device Patch Management Procedure with named roles and routing rules. ¹

2) Build and maintain a patch-relevant device inventory

1. Maintain an inventory that supports patch decisions, not just asset counts. Track device model, software/firmware versions, network location, owner, patient care criticality, and manufacturer support contacts.
2. Map dependencies (device management servers, remote access tools, middleware).
3. Identify “patch constraints” such as manufacturer-only patching, validation requirements, maintenance windows, and warranty/support implications.

Evidence tip: Auditors accept imperfect inventories less readily here because patching is device-specific and manufacturer-specific.

3) Establish manufacturer coordination workflows (third-party coordination)

1. Create a manufacturer contact register and escalation path for urgent issues.
2. Require documented manufacturer guidance for patch applicability and installation method where the manufacturer controls patching or supportability.
3. Define how you handle devices supported by third parties (service providers, integrators). Your process should still capture manufacturer constraints and clinical engineering approval. ¹

Control objective: “We can prove we coordinated with the manufacturer/third party and did not break support terms or clinical safety constraints.” ¹

4) Patch triage and risk-based decisioning (with clinical engineering)

1. Triage new patches/advisories into at least: “evaluate,” “test/validate,” “deploy,” “defer with controls.”
2. Involve clinical engineering in the decision to schedule downtime and confirm clinical impacts.
3. Record risk acceptance decisions when patching is deferred. The record should include why, who approved, what controls mitigate risk, and the planned revisit trigger. ¹

5) Validate patches before clinical deployment

1. Define validation methods appropriate to the device class:
   • Lab test environment (if available)
   • Pilot on non-production or low-risk units
   • Manufacturer-led validation with documented outcomes
2. Document validation results: what was tested, success criteria, issues found, and sign-off.
3. Confirm clinical acceptance before broad rollout (biomed/clinical engineering sign-off). ¹

6) Deploy with controlled change management

1. Schedule deployments around clinical operations (planned windows, back-out plans).
2. Use a tracked method of deployment (manufacturer tool, endpoint management tool, on-site service visit), with a ticket for each change event or batch.
3. Verify and record post-deployment state (version, status, functional check completion).

7) Handle exceptions with compensating controls

When patching can’t proceed (manufacturer delay, safety concerns, uptime constraints), define required compensating controls such as:

• Network segmentation or access restrictions for the device VLAN
• Tight remote access controls for service connections
• Monitoring/alerting for abnormal behavior
• Physical access controls and port restrictions

Important: Compensating controls do not replace patching. They document interim risk treatment and give you something defensible during audit.

8) Measure and report program health (without inventing metrics)

Pick operational metrics you can defend with your own system data, for example:

• Devices with known patch constraints
• Patch decisions pending manufacturer guidance
• Deferred patches with documented approvals and next review triggers
• Validation backlog by device class

(Keep numbers internal. The requirement is evidence of governance and coordination, not a specific industry benchmark.) ¹

Required evidence and artifacts to retain

Use this as an audit-ready checklist:

Governance

• Medical Device Patch Management Procedure and RACI ¹
• Defined validation criteria and change control requirements ¹

Inventory and classification

• Medical device inventory with software/firmware versions and owners
• Criticality classification and patch constraints register

Manufacturer/third-party coordination

• Manufacturer advisories, support statements, or service bulletins captured in tickets
• Communications log or ticket notes showing coordination and outcomes ¹

Patch lifecycle records

• Triage decisions and risk assessments (including deferrals and approvals)
• Validation/test results and sign-offs ¹
• Change tickets, implementation logs, and post-deploy verification evidence

Exception management

• Risk acceptance memos or GRC entries for deferred patches
• Compensating controls evidence (segmentation configs, monitoring rules, access reviews)

Practical note: If you adopt Daydream to run third-party and control evidence collection workflows, set up an evidence request package for manufacturers and service providers (patch guidance, validation notes, supportability confirmation) and tie those uploads directly to each device family and patch ticket. That reduces “lost in email” audit gaps.

Common exam/audit questions and hangups

• “Show me your specialized procedure for medical device patching. How is it different from standard IT patching?” ¹
• “Where is clinical engineering involved, and what do they sign off on?” ¹
• “How do you coordinate with manufacturers and document that coordination?” ¹
• “Pick a device and walk me through the last patch end-to-end: advisory, triage, validation, deployment, verification.”
• “What happens when you can’t patch? Who approves deferral and what controls are in place?”

Hangups auditors often fixate on:

• No reliable version tracking for device software/firmware.
• Patch decisions made in informal channels with no durable record.
• Validation claimed but not evidenced.

Frequent implementation mistakes and how to avoid them

1. Treating medical devices like laptops. Avoid pushing patches via standard tools without confirming manufacturer support and clinical engineering approval. ¹
2. No validation proof. A meeting note that says “tested” rarely survives scrutiny; keep test cases, screenshots, release notes, or manufacturer validation artifacts tied to the ticket. ¹
3. Deferrals without compensating controls. If you defer, document network and access controls that reduce exploitability, and set a clear revisit trigger.
4. Inventory without patch relevance. Asset lists that omit versions, models, or owners can’t support a defensible patch program.

Enforcement context and risk implications

No public enforcement cases were provided in the source catalog for this requirement. The practical risk is operational: failing to coordinate patching with manufacturers and clinical engineering increases the chance of unsafe changes, unplanned downtime, or unsupported configurations in clinical environments. HICP frames medical device patching as a coordinated, validated process for that reason. ¹

A practical 30/60/90-day execution plan

First 30 days (stabilize the workflow)

• Publish the medical device patch procedure, including manufacturer coordination and clinical engineering sign-off points. ¹
• Stand up a single queue for device advisories and patch intake.
• Identify the highest-risk device families and confirm manufacturer contacts and service ownership.

By 60 days (make it auditable)

• Produce a patch-relevant device inventory for in-scope devices (versions, owners, criticality, constraints).
• Implement a standard ticket template that captures: manufacturer guidance, validation results, deployment verification, or deferral approvals. ¹
• Formalize compensating control options and the approval path for deferrals.

By 90 days (make it repeatable)

• Run at least one full-cycle patch event with documented validation and clinical engineering acceptance, then review gaps.
• Add reporting that highlights pending manufacturer responses, validation backlog, and deferred patches with controls.
• If using Daydream, automate evidence collection from third parties and map artifacts to each device family and patch record so audit response is a pull, not a scramble.

Frequently Asked Questions

Do we have to patch every medical device immediately when a patch is released?

HICP Practice 9.6 does not state a timing mandate; it requires specialized procedures with manufacturer and clinical engineering coordination and validation before clinical deployment. If you defer, document the decision and compensating controls so the risk treatment is defensible. ¹

What if the manufacturer says only they can apply the patch?

Treat the manufacturer as a third party step in your workflow. Open and track a ticket, capture manufacturer guidance and scheduling, and retain evidence of completion and post-change verification with clinical engineering sign-off. ¹

How do we validate patches if we don’t have a test lab?

Use a defined alternative validation approach such as a controlled pilot on non-critical units or manufacturer-provided validation evidence, then document the acceptance decision. The key is that validation occurs before broad clinical deployment and is recorded. ¹

Are clinical engineering and biomed the same for this requirement?

They are often overlapping functions, but your procedure should name the accountable clinical/biomed owner for patch validation and acceptance. Auditors care that the right clinical stakeholder is consistently involved and signs off. ¹

What evidence will satisfy an auditor that we “coordinated with manufacturers”?

Keep durable records in your ticketing or GRC system: manufacturer advisories, emails or portal confirmations, supportability statements, installation instructions, and any manufacturer-performed service documentation. Tie that evidence to each patch decision and device family. ¹

Can compensating controls replace patching for end-of-life devices?

Compensating controls can reduce risk when patches aren’t available, but you still need a documented decision process and governance around continued clinical use. Maintain clear ownership, segmentation/access controls, and a plan for remediation or replacement tied to risk. ¹

Footnotes

1. HICP 2023 - 405(d) Health Industry Cybersecurity Practices